Video

Dr. Goetz on the Impact of the PALOMA-2 Trial in ER+/HER2- Breast Cancer

Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the impact of the phase 3 PALOMA-2 trial (NCT01740427) in estrogen receptor (ER)–positive/HER2-negative advanced breast cancer.

The trial compared letrozole (Femara) in combination with palbociclib (Ibrance) vs letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative advanced breast cancer, Goetz explains.

Additional trials in the first-line setting, such as the phase 3 monarchE (NCT03155997) and MONALEESA-2 (NCT01958021) trials, tested different CDK4/6 inhibitors in combination with endocrine therapy, Goetz continues. The trials confirmed a benefit in progression-free survival with the addition of a CDK4/6 inhibitor to treatment, and as data have matured, investigators are beginning to gather overall survival data, Goetz concludes.

Related Videos
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
MATT WAGAR, MD
Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA